What Happens to Endometriomas After Menopause? A Non-Invasive Follow-Up Focusing on Ultrasound Features and Clinical Changes

Consuelo Russo, Pisante A, Ambra Pisante, Fabrizi F, Francesca Fabrizi, Aikaterini Selntigia, Selntigia A, Giulia Monaco, Monaco G, Elvira Nocita, Nocita E, Veronica Yacoub, Yacoub V, Soreca G, Giorgia Soreca, Ercoli A, Alfredo Ercoli, Caterina Exacoustos, Exacoustos C
Journal of clinical ultrasound : JCU · 2026 · doi:10.1002/jcu.70266 · PMID:42121389 · W7161018343
article OA: closed public-domain-us
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study describes the ultrasound features and clinical course of ovarian endometriomas in postmenopausal women, finding early dimensional reduction and later structural remodeling without malignant changes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This retrospective observational study followed postmenopausal women with at least one ovarian endometrioma identified by transvaginal ultrasound, using baseline and 12- and 24-month clinical and ultrasound assessments (2018–2023, University of Rome Tor Vergata), with endometrioma size classified by the #Enzian system. Among 41 women (45 endometriomas), most lesions were unilocular with “ground glass” echogenicity and were predominantly #Enzian O1 at the first postmenopausal scan, and the key findings were significant early size regression from pre- to postmenopause with continued decline at 12 and 24 months. Later, morpho-structural changes emerged, particularly an increase in wall irregularities, while vascularization stayed minimal and serum epithelial tumor markers remained normal, with no suspicious or malignant transformations observed and pain symptoms stable. The paper’s major limitation is its retrospective design and the relatively small, single-center cohort. This paper is centrally about endometriosis — it longitudinally characterizes how ovarian endometriomas evolve after menopause using ultrasound and clinical follow-up.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVES: To describe the longitudinal ultrasound features and clinical course of ovarian endometriomas in postmenopausal women, aiming to improve diagnostic accuracy and guide follow-up strategies. METHODS: This retrospective observational study included postmenopausal women with at least one ovarian endometrioma identified by transvaginal ultrasound (TVUS) and monitored for a minimum of 24 months at the University of Rome Tor Vergata (2018-2023). All had a known premenopausal endometriosis detected by TVUS at our Unit. Clinical and ultrasound assessments were conducted at baseline and at 12 and 24 months, recording changes in TVUS characteristics and symptoms. Endometrioma size was classified using the #Enzian classification. RESULTS: Forty-one postmenopausal patients (mean age 53.5 ± 6.4 years) were included. A total of 45 endometriomas were analyzed, mostly unilocular (100%), with a typical "ground glass" echogenicity (75.6%) and classified as #Enzian O1 (82.2%) at the first postmenopausal scan. A significant early dimensional reduction occurred between pre- and postmenopause: the mean maximum diameter decreased from 29.0 ± 15.2 to 20.6 ± 9.7 mm (p = 0.002), and the mean diameter from 24.5 ± 13.1 to 17.9 ± 8.9 mm (p = 0.006), with continued decline at 12 and 24 months (p < 0.05). In contrast, morpho-structural changes emerged later during follow-up, with the proportion of cysts showing wall irregularities rising from 11.1% in premenopause to 38.6% at 24 months (p = 0.003). Vascularization remained minimal throughout. All serum epithelial tumor markers stayed within normal ranges, no suspicious or malignant transformations were observed, and pain symptoms remained stable during follow-up. CONCLUSIONS: Ovarian endometriomas in postmenopausal women exhibit a benign evolution, characterized by early dimensional regression and later structural remodeling without malignant features. Regular ultrasound surveillance remains essential to recognize benign morphologic changes, avoid unnecessary surgery, and promptly identify lesions requiring further evaluation.
Full text 2,500 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Objectives To describe the longitudinal ultrasound features and clinical course of ovarian endometriomas in postmenopausal women, aiming to improve diagnostic accuracy and guide follow-up strategies.

Methods

This retrospective observational study included postmenopausal women with at least one ovarian endometrioma identified by transvaginal ultrasound (TVUS) and monitored for a minimum of 24 months at the University of Rome Tor Vergata (2018–2023). All had a known premenopausal endometriosis detected by TVUS at our Unit. Clinical and ultrasound assessments were conducted at baseline and at 12 and 24 months, recording changes in TVUS characteristics and symptoms. Endometrioma size was classified using the #Enzian classification.

Results

Forty-one postmenopausal patients (mean age 53.5 ± 6.4 years) were included. A total of 45 endometriomas were analyzed, mostly unilocular (100%), with a typical “ground glass” echogenicity (75.6%) and classified as #Enzian O1 (82.2%) at the first postmenopausal scan. A significant early dimensional reduction occurred between pre- and postmenopause: the mean maximum diameter decreased from 29.0 ± 15.2 to 20.6 ± 9.7 mm (p = 0.002), and the mean diameter from 24.5 ± 13.1 to 17.9 ± 8.9 mm (p = 0.006), with continued decline at 12 and 24 months (p < 0.05). In contrast, morpho-structural changes emerged later during follow-up, with the proportion of cysts showing wall irregularities rising from 11.1% in premenopause to 38.6% at 24 months (p = 0.003). Vascularization remained minimal throughout. All serum epithelial tumor markers stayed within normal ranges, no suspicious or malignant transformations were observed, and pain symptoms remained stable during follow-up.

Conclusions

Ovarian endometriomas in postmenopausal women exhibit a benign evolution, characterized by early dimensional regression and later structural remodeling without malignant features. Regular ultrasound surveillance remains essential to recognize benign morphologic changes, avoid unnecessary surgery, and promptly identify lesions requiring further evaluation. Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Outcome instruments

Enzian

Condition tags

endometriosisendometrioma

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Source provenance

europepmc
last seen: 2026-08-02T06:10:09.037253+00:00
openalex
last seen: 2026-08-02T06:03:29.899990+00:00
pubmed
last seen: 2026-08-02T06:05:19.105842+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine